Dr. Nathaniel Buteyn earned his Ph.D. in molecular, cellular and developmental biology from Ohio State University and his B.S. in biotechnology from Calvin College. His graduate work focused on the development of novel immunotherapies for the treatment of acute myeloid leukemia. These included inducing fratricidal blast-to-blast killing utilizing anti-CD38 monoclonal antibody Daratumumab in conjunction with all-trans retinoic acid and the reactivation of innate immunity/NK cell cytotoxicity through activation of the intracellular pathogen recognition receptor NOD2 with a synthetic bacterial peptide, muramyl tripeptide phosphatidylethanolamine. Dr. Buteyn’s lab skills include mammalian cell culture, murine drug models, qPCR, Western blots, cytotoxicity assays and flow cytometry. In 2020, he joined the lab of Dr. Tim Triche, Jr., as a postdoctoral fellow.
Dr. Buteyn’s research focuses on identification and characterization of distinct immunophenotypes that define subsets of poor-risk and/or relapsed/refractory pediatric leukemias. Tailoring treatments based on these subsets, in addition to aberrant metabolic and developmental pathways, may provide novel therapeutic avenues for treating at-risk patients while reimagining the conventional classification of disease based on cytogenetics.
Ph.D. in molecular, cellular and developmental biology, Ohio State University
Thesis: Role of innate immunity activators in the treatment of acute myeloid leukemia (Advisor: Susheela Tridandapani, Ph.D.)
B.S. in biotechnology, Calvin College
To view a list of selected publications click below.
Buteyn NJ, Santhanam R, Merchand-Reyes G, Murugesan RA, Dettorre GM, Byrd JC, Sarkar A, Vasu S, Mundy-Bosse BL, Butchar JP, Tridandapani S. 2020. Activation of the intracellular pattern recognition receptor NOD2 promotes acute myeloid leukemia (AML) cell apoptosis and provides a survival advantage in an animal model of AML. J Immunol 204(7):1988–1997.
Merchand-Reyes G, Robledo-Avila FH, Buteyn NJ, Gautam S, Santhanam R, Fatehchand K, Mo X, Partida-Sanchez S, Butchar JP, Tridandapani S. 2019. CD31 acts as a checkpoint molecule and is modulated by FcγR-mediated signaling in monocytes. J Immunol 203(12):3216–3224.
Buteyn NJ, Fatehchand K, Santhanam R … Tridandapani S. 2018. Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia. Int Immunol 30(8):375–383
Fatehchand K, McMichael EL, Reader BF … Buteyn NJ … Tridandapani S. 2016. Interferon-γ promotes antibody-mediated fratricide of acute myeloid leukemia cells. J Biol Chem 291(49):25656–25666.